Global Primary Sclerosing Cholangitis Treatment Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Liver Transplantation Operation
  • 1.4.3 UDCA Drugs
  • 1.4.4 PSC Drugs
• 1.5 Market by Application
  • 1.5.1 Global Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2025)
  • 1.5.2 Hospital
  • 1.5.3 Clinics
  • 1.5.4 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Primary Sclerosing Cholangitis Treatment Market Size
• 2.2 Primary Sclerosing Cholangitis Treatment Growth Trends by Regions
  • 2.2.1 Primary Sclerosing Cholangitis Treatment Market Size by Regions (2019-2025)
  • 2.2.2 Primary Sclerosing Cholangitis Treatment Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players

• 3.1 Primary Sclerosing Cholangitis Treatment Market Size by by Players
  • 3.1.1 Global Primary Sclerosing Cholangitis Treatment Revenue by by Players (2014-2019)
  • 3.1.2 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by by Players (2014-2019)
  • 3.1.3 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio (CR5 and HHI)
• 3.2 Primary Sclerosing Cholangitis Treatment Key Players Head office and Area Served
• 3.3 Key Players Primary Sclerosing Cholangitis Treatment Product/Solution/Service
• 3.4 Date of Enter into Primary Sclerosing Cholangitis Treatment Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Primary Sclerosing Cholangitis Treatment Market Size by Type (2014-2019)
• 4.2 Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2014-2019)

5 North America

• 5.1 North America Primary Sclerosing Cholangitis Treatment Market Size (2014-2019)
• 5.2 Primary Sclerosing Cholangitis Treatment Key Players in North America
• 5.3 North America Primary Sclerosing Cholangitis Treatment Market Size by Type
• 5.4 North America Primary Sclerosing Cholangitis Treatment Market Size by Application

6 Europe

• 6.1 Europe Primary Sclerosing Cholangitis Treatment Market Size (2014-2019)
• 6.2 Primary Sclerosing Cholangitis Treatment Key Players in Europe
• 6.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type
• 6.4 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application

7 China

• 7.1 China Primary Sclerosing Cholangitis Treatment Market Size (2014-2019)
• 7.2 Primary Sclerosing Cholangitis Treatment Key Players in China
• 7.3 China Primary Sclerosing Cholangitis Treatment Market Size by Type
• 7.4 China Primary Sclerosing Cholangitis Treatment Market Size by Application

8 Japan

• 8.1 Japan Primary Sclerosing Cholangitis Treatment Market Size (2014-2019)
• 8.2 Primary Sclerosing Cholangitis Treatment Key Players in Japan
• 8.3 Japan Primary Sclerosing Cholangitis Treatment Market Size by Type
• 8.4 Japan Primary Sclerosing Cholangitis Treatment Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size (2014-2019)
• 9.2 Primary Sclerosing Cholangitis Treatment Key Players in Southeast Asia
• 9.3 Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size by Type
• 9.4 Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size by Application

10 India

• 10.1 India Primary Sclerosing Cholangitis Treatment Market Size (2014-2019)
• 10.2 Primary Sclerosing Cholangitis Treatment Key Players in India
• 10.3 India Primary Sclerosing Cholangitis Treatment Market Size by Type
• 10.4 India Primary Sclerosing Cholangitis Treatment Market Size by Application

11 Central & South America

• 11.1 Central & South America Primary Sclerosing Cholangitis Treatment Market Size (2014-2019)
• 11.2 Primary Sclerosing Cholangitis Treatment Key Players in Central & South America
• 11.3 Central & South America Primary Sclerosing Cholangitis Treatment Market Size by Type
• 11.4 Central & South America Primary Sclerosing Cholangitis Treatment Market Size by Application

12 International Players Profiles

• 12.1 Allergan
  • 12.1.1 Allergan Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Primary Sclerosing Cholangitis Treatment Introduction
  • 12.1.4 Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019))
  • 12.1.5 Allergan Recent Development
• 12.2 Glenmark
  • 12.2.1 Glenmark Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Primary Sclerosing Cholangitis Treatment Introduction
  • 12.2.4 Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
  • 12.2.5 Glenmark Recent Development
• 12.3 Impax Laboratories
  • 12.3.1 Impax Laboratories Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Primary Sclerosing Cholangitis Treatment Introduction
  • 12.3.4 Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
  • 12.3.5 Impax Laboratories Recent Development
• 12.4 Mylan
  • 12.4.1 Mylan Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Primary Sclerosing Cholangitis Treatment Introduction
  • 12.4.4 Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
  • 12.4.5 Mylan Recent Development
• 12.5 Teva Pharmaceuticals
  • 12.5.1 Teva Pharmaceuticals Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Primary Sclerosing Cholangitis Treatment Introduction
  • 12.5.4 Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
  • 12.5.5 Teva Pharmaceuticals Recent Development
• 12.6 Dr. Falk Pharma
  • 12.6.1 Dr. Falk Pharma Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Primary Sclerosing Cholangitis Treatment Introduction
  • 12.6.4 Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
  • 12.6.5 Dr. Falk Pharma Recent Development
• 12.7 Daewoong Pharmaceutical
  • 12.7.1 Daewoong Pharmaceutical Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Primary Sclerosing Cholangitis Treatment Introduction
  • 12.7.4 Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
  • 12.7.5 Daewoong Pharmaceutical Recent Development
• 12.8 Epic Pharma
  • 12.8.1 Epic Pharma Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Primary Sclerosing Cholangitis Treatment Introduction
  • 12.8.4 Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
  • 12.8.5 Epic Pharma Recent Development
• 12.9 Mitsubishi Tanabe Pharma
  • 12.9.1 Mitsubishi Tanabe Pharma Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Primary Sclerosing Cholangitis Treatment Introduction
  • 12.9.4 Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
  • 12.9.5 Mitsubishi Tanabe Pharma Recent Development
• 12.10 Lannett
  • 12.10.1 Lannett Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Primary Sclerosing Cholangitis Treatment Introduction
  • 12.10.4 Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2014-2019)
  • 12.10.5 Lannett Recent Development
• 12.11 Bruschettini
• 12.12 Shanghai Pharma
• 12.13 Grindeks
• 12.14 Acorda Therapeutics
• 12.15 Gilead Sciences
• 12.16 Intercept Pharmaceuticals
• 12.17 Shire Plc
• 12.18 NGM Biopharmaceuticals
• 12.19 Conatus Pharmaceuticals
• 12.20 Durect Corporation
• 12.21 Sirnaomics
• 12.22 Shenzhen HighTide Biopharmaceuticals

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Product (2019-2025)
• 13.2 Market Size Forecast by Application (2019-2025)
• 13.3 Market Size Forecast by Regions
• 13.4 North America
• 13.5 Europe
• 13.6 China
• 13.7 Japan
• 13.8 Southeast Asia
• 13.9 India
• 13.10 Central & South America

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 15.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer